Counterpoint Biomedica
Counterpoint Biomedica LLC is a preclinical stage bio-pharmaceutical company focused on advanced tumor-targeting platforms and precision cancer diagnostics. Their mission is to enhance the performance of FDA-approved chemotherapeutic and biological agents through pro-active tumor targeting, and to apply these platform biotechnologies to cancer diagnostics and liquid biopsies. They develop proprietary tumor-targeting platforms, including onco-aptamers, to improve drug delivery, efficacy, and safety in cancer treatment.
Industries
Nr. of Employees
small (1-50)
Counterpoint Biomedica
Counterpoint Biomedica LLC, c/o Dr Erlinda M. Gordon, MD, 2811 Wilshire Blvd., Suite 420, Santa Monica, California 90403
Products
Tumor-targeting adaptor platform (aptamer-based)
A platform of bifunctional adaptor molecules combining a drug-binding domain and a tumor-targeting domain designed to bind approved anticancer drugs non-covalently and direct them to tumor lesions.
Targeted diagnostic reagents for CTC capture and liquid biopsy
Antibodies and polypeptide aptamers engineered to recognize pericellular collagens, vimentin, and other tumor-associated markers for capture and analysis of circulating tumor cells.
Tumor-targeted immunotherapy constructs
Approaches that combine tumor-targeting adaptors with immunomodulatory agents to concentrate immune-stimulating factors at tumor sites.
Tumor-targeting adaptor platform (aptamer-based)
A platform of bifunctional adaptor molecules combining a drug-binding domain and a tumor-targeting domain designed to bind approved anticancer drugs non-covalently and direct them to tumor lesions.
Targeted diagnostic reagents for CTC capture and liquid biopsy
Antibodies and polypeptide aptamers engineered to recognize pericellular collagens, vimentin, and other tumor-associated markers for capture and analysis of circulating tumor cells.
Tumor-targeted immunotherapy constructs
Approaches that combine tumor-targeting adaptors with immunomodulatory agents to concentrate immune-stimulating factors at tumor sites.
Services
Licensing of patent rights and collaboration opportunities to develop or commercialize tumor-targeting adaptor technologies and related diagnostics.
Licensing of patent rights and collaboration opportunities to develop or commercialize tumor-targeting adaptor technologies and related diagnostics.
Expertise Areas
- Tumor-targeted drug delivery
- Aptamer and polypeptide engineering
- Targeted diagnostics and liquid biopsy development
- Preclinical oncology translational research
Key Technologies
- Aptamer-based tumor-targeting adaptors
- Non-covalent drug–adaptor complexation
- Targeting of exposed tumor-associated extracellular matrix proteins (collagen/vimentin)
- Antibody-based targeting reagents
News & Updates
Restoration of DeltaRex-G to the Cancer Clinic in 2019
Counterpoint Biomedica LLC assisted in the restoration of DeltaRex-G to the Cancer Clinic.
Gained New Patents for Targeting Pharmaceutical Agents, Cancer Stem Cells, and Targeted Immuno-therapy
Recently, Counterpoint Biomedica LLC gained new patents for targeting pharmaceutical agents, capture and characterization of cancer stem cells, and targeted immuno-therapy.
Restoration of DeltaRex-G to the Cancer Clinic in 2019
Counterpoint Biomedica LLC assisted in the restoration of DeltaRex-G to the Cancer Clinic.
Gained New Patents for Targeting Pharmaceutical Agents, Cancer Stem Cells, and Targeted Immuno-therapy
Recently, Counterpoint Biomedica LLC gained new patents for targeting pharmaceutical agents, capture and characterization of cancer stem cells, and targeted immuno-therapy.